Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways
<p>Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor Receptor (PDGFR) α...
Saved in:
Main Authors: | Kenji Ichikawa (Author), Saori Watanabe Miyano (Author), Yusuke Adachi (Author), Masahiro Matsuki (Author), Kiyoshi Okamoto (Author), Junji Matsui (Author) |
---|---|
Format: | Book |
Published: |
Global Journal of Cancer Therapy - Peertechz Publications,
2016-07-02.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor
Published: (2020) -
Angiogenesis in Cancers
Published: (2023) -
Tumor Angiogenesis
Published: (2012) -
Hericium erinaceus powder inhibits the growth of Porphyromonas gingivalis
by: Hirono Ichikawa, et al.
Published: (2021) -
Tumor Angiogenesis and Modulators
Published: (2022)